All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know GvHD.
The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View GvHD content recommended for you
Response dynamics to belumosudil: ROCKstar ad hoc analysis
Do you know... Based on an ad hoc analysis of the ROCKstar trial, among patients who responded to belumosudil (N = 114), the most rapid responses were observed in which organ systems?
Chronic graft-versus-host disease (cGvHD) is a heterogenous, multiorgan complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT),1 affecting up to 70% of transplant recipients.2 In the phase II ROCKstar trial (NCT03640481), belumosudil, a selective ROCK2 inhibitor, demonstrated efficacy across all organ systems involved in cGvHD.2 However, the timing and dynamics of organ-specific responses remain poorly characterized. An ad hoc analysis of the ROCKstar trial, evaluating time to response (TTR) and patterns of organ-specific improvement over the first year of belumosudil therapy, was presented by Zachariah DeFilipp at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, Dec 6–9, 2025, Orlando, US.3
Results from this analysis showed that response kinetics varied by organ, highlighting the importance of managing clinical expectations and adapting treatment duration according to organ-specific response patterns.3
This educational resource is independently supported by Sanofi. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In steroid-refractory acute GvHD, which factor most strongly limits your use of mesenchymal stromal cells in routine clinical practice?
